C
CING
Cingulate Inc
5.17
-0.04-0.77%After Hours: 5.17 0.00 0.00%19:43 09/10 EDT
OPEN/PREV CLOSE5.17/5.21
TODAY RANGE5.16-5.41
VOL118.08K
MARKET CAP75.18M
52 WEEK RANGE3.160-11.89
AVG VOL (3M)220.44K
% TURNOVER0.81%
TURNOVER--
P/E (TTM)-1.4046
% RANGE4.80%
EPS(TTM)-3.6807
P/E(FORWARD)-2.4250
P/B3.061
BVPS1.689
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP53.89M
SHARES OUTSTANDING14.54M
NEXT EARNINGS--
FREE FLOAT10.42M
LOT SIZE1
EX-DATE08/09/2024
News
Press Releases
Financial Reports
Profile
Dow Jones·08/24 17:16
Cingulate Price Target Cut to $9.00/Share From $10.00 by Roth Capital
Benzinga·08/24 17:05
Roth Capital Reiterates Buy on Cingulate, Lowers Price Target to $9
TipRanks·08/23 22:15
Roth MKM Remains a Buy on Cingulate Inc (CING)
TipRanks·08/23 22:10
Cingulate price target lowered to $9 from $10 at Roth Capital
Dow Jones·08/20 10:04
Cingulate Price Target Cut to $44.00/Share From $52.00 by Ascendiant Capital
Dow Jones·08/20 10:04
Cingulate Is Maintained at Buy by Ascendiant Capital
Benzinga·08/20 09:54
Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $44
TipRanks·08/14 12:55
Maxim Group Keeps Their Buy Rating on Cingulate Inc (CING)
Seeking Alpha·08/13 19:14
Cingulate reports Q2 results
Benzinga·08/13 12:57
Cingulate Q2 EPS $(0.45) Beats $(0.63) Estimate
Dow Jones·08/13 12:31
*Cingulate 2Q Loss $5.9M >CINGW
TipRanks·08/11 13:20
Cingulate publishes peer-reviewed data on CTx-1301 pharmacokinetic profile
TipRanks·07/31 15:46
Roth MKM Sticks to Their Buy Rating for Cingulate Inc (CING)
Same Industry
Name/Symbol
Change%
Price